{"id":6996,"date":"2025-05-28T11:05:17","date_gmt":"2025-05-28T09:05:17","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=pipelines&p=6996"},"modified":"2025-07-10T11:04:09","modified_gmt":"2025-07-10T09:04:09","slug":"tislelizumab-pd-1-mab-2","status":"publish","type":"pipelines","link":"https:\/\/beonemedaffairs.com\/us\/pipelines\/6996\/tislelizumab-pd-1-mab-2\/","title":{"rendered":"Tislelizumab (PD-1 mAb)"},"content":{"rendered":"","protected":false},"template":"","meta":{"_acf_changed":false,"editor_notices":[]},"class_list":["post-6996","pipelines","type-pipelines","status-publish","hentry","molecule-tislelizumab","compound_type-mab"],"acf":{"indications_repeater":[{"indication":"R\/R cHL","disease_state":null,"phase":3,"countries":[],"status":"planned"}],"cancer_type":["190"],"compound_type":420,"custom_link":{"title":"Mode of Action video","url":"https:\/\/beonemedaffairs.com\/us\/936\/tislelizumab-moa-video\/","target":""}},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/pipelines\/6996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/pipelines"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/pipelines"}],"acf:term":[{"embeddable":true,"taxonomy":"compound_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/compound_type\/420"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}